Vitamin B12 Dosage Guide: Protocols, Calculator & Safety

Vitamin B12 is exceptionally compatible with nearly all other supplements and exerts its main benefits through the one-carbon methylation cycle, making it a natural pairing with folate, glycine, and methyl-donor nutrients. The practical stacking considerations focus on co-factor completeness, absorption optimization, and avoidance of counterproductive combinations.

B12 + FOLATE (MANDATORY PAIR FOR FUNCTIONAL METHYLATION). These two vitamins are inseparable from a metabolic standpoint. Methionine synthase uses methyl-B12 to transfer a methyl group from 5-MTHF to homocysteine, producing methionine and THF. Without adequate folate, methionine synthase has no substrate; without adequate B12, folate is trapped as 5-MTHF and cannot recycle. Supplementing one without the other is common in practice (high-dose folic acid in fortified foods, B12-only injections in pernicious anemia patients) and is not wrong, but for someone optimizing methylation or addressing elevated homocysteine, both should be adequate. Typical pairing: B12 500-1000 mcg + folate 400-800 mcg daily. For individuals with MTHFR polymorphisms or concerns about synthetic folic acid, methylfolate (L-5-MTHF) 400-800 mcg is reasonable. See /compound/glycine for the one-carbon metabolism cross-talk.

B12 + B6 (CLASSIC HOMOCYSTEINE-LOWERING TRIO). Vitamin B6 supports the transsulfuration pathway that converts homocysteine to cystathionine and ultimately cysteine and glutathione, complementing the B12-dependent remethylation route. The classic "B-trio" for homocysteine management is B12 + folate + B6, as used in VITACOG and the VITATOPS cardiovascular trials. Typical B6 dose 10-25 mg/day as P5P (pyridoxal-5-phosphate) or pyridoxine HCl. Avoid chronic doses above 100 mg/day because of peripheral neuropathy risk.

B12 + CHOLINE/BETAINE. Trimethylglycine (betaine/TMG) serves as an alternative methyl donor via betaine-homocysteine methyltransferase (BHMT) in liver, providing a B12-independent remethylation route. For users with persistent elevated homocysteine despite B12/folate repletion, betaine 500-3000 mg/day can further reduce homocysteine. Choline supports hepatic methylation more broadly. These are particularly relevant in users with genetic variations in BHMT or PEMT pathways.

B12 + IRON. Patients with combined iron and B12 deficiency (common in the elderly, in vegans, and post-bariatric surgery) need both repleted; treating one without the other leaves a partial response. Iron studies (ferritin, transferrin saturation) are commonly ordered alongside B12 workup.

B12 + VITAMIN D. No direct metabolic interaction, but both are commonly deficient in the same populations (elderly, limited sun exposure, vegans who avoid fortified foods) and are reasonable to co-supplement. See /compound/vitamin-d.

B12 + MAGNESIUM AND ZINC. Methionine synthase requires multiple micronutrient cofactors indirectly, and general micronutrient adequacy supports the entire methylation system. Magnesium is required for ATP-dependent activation of methionine to SAMe. Zinc supports numerous enzymes in the broader sulfur amino acid pathway. See /compound/magnesium and /compound/zinc.

B12 + NAC/GLUTATHIONE. The transsulfuration pathway produces cysteine, which is the rate-limiting substrate for glutathione synthesis. Users aiming to support antioxidant systems benefit from a complete pathway: B12+folate+B6 feeds remethylation and transsulfuration, while NAC or glutathione directly supports the downstream antioxidant pool. See /compound/nac and /compound/glutathione.

B12 + CALCIUM. Intestinal absorption of the B12-intrinsic factor complex by the cubam receptor is calcium-dependent. Metformin's interference with B12 absorption operates partly through calcium-dependent binding, and oral calcium 500-1200 mg/day has been shown to partially reverse metformin-induced B12 deficiency (PMID 16567804). Most users don't need specific calcium supplementation for this purpose, but the mechanism explains why combined calcium+B12 regimens work in metformin patients.

B12 + OMEGA-3. No direct interaction, but both are commonly inadequate in Western diets and are reasonable components of foundational supplementation. Homocysteine elevation and omega-3 inadequacy are independent cardiovascular risk factors.

AVOID HIGH-DOSE NIACIN IN COMBINATION. Niacin (B3) at pharmacological doses can increase homocysteine, partially counteracting the homocysteine-lowering effect of B12/folate. This interaction is modest and rarely clinically significant but worth flagging for users on niacin for lipid management who are also concerned about homocysteine.

NITROUS OXIDE. Absolute contraindication during active B12 therapy if possible, and major caution in anyone with marginal B12 status considering recreational nitrous oxide use. N2O irreversibly oxidizes the cobalt in cobalamin, inactivating methionine synthase for days to weeks. In patients with low-normal B12, a single N2O anesthesia exposure can precipitate acute neurological deterioration.

CAFFEINE AND ALCOHOL. No direct B12 interactions, but chronic heavy alcohol use damages gastric parietal cells (reducing intrinsic factor) and the terminal ileum (reducing absorption), and alcoholics commonly have combined folate and B12 deficiency. Alcohol reduction improves B12 status independent of supplementation.

PROBIOTICS. Some bacterial species produce bioactive B12, and probiotic supplementation has been proposed as a plant-based B12 source. In practice, this is unreliable; vegans should supplement B12 directly rather than depend on probiotic production.

H. PYLORI TREATMENT. Eradication of chronic H. pylori infection can partially restore gastric acid production and B12 absorption in patients whose deficiency is driven by H. pylori-induced atrophic gastritis.

Vitamin B12 is sold over the counter in the US and most jurisdictions in doses from 100 mcg to 10,000 mcg per unit; prescription injectable forms (cyanocobalamin, hydroxocobalamin) are also available. Dosing should be guided by absorption physiology, indication, and formulation rather than by the RDA, which was designed around the assumption of intact absorption.

RDA AND BIOCHEMICAL CONTEXT. The RDA for adults is 2.4 mcg/day (slightly higher in pregnancy and lactation). This figure reflects the minimum oral intake assumed to maintain adequate status in a population with normal IF-mediated absorption (receptor-limited to roughly 1.5-2 mcg per meal). In practice, population data from NHANES and European surveys show that actual dietary intake in omnivores is typically 4-10 mcg/day, vegetarians 2-4 mcg/day, and vegans under 1 mcg/day — with the vegan population reliably producing biochemical deficiency without supplementation. The RDA is also inadequate for the substantial fraction of adults over 50 with food-bound B12 malabsorption from atrophic gastritis, where synthetic supplemental B12 (which does not require acid release from food) is required.

ORAL DOSING. For general maintenance in healthy adults with no deficiency risk factors, 100-500 mcg daily oral is sufficient and typical in multivitamins. For insurance dosing in older adults or users with any risk factor, 500-1000 mcg daily is reasonable. For active repletion of deficiency without IF issues, 1000 mcg daily is standard. For pernicious anemia or severe malabsorption using oral therapy, 2000 mcg daily — the classic Kuzminski trial dose — achieves equivalent outcomes to monthly IM injections. Higher doses (5000-10000 mcg) are commonly sold but offer no meaningful advantage over 2000 mcg for standard indications and are inefficient (diminishing returns on passive diffusion absorption).

SUBLINGUAL DOSING. Sublingual tablets, lozenges, and sprays bypass some gastrointestinal absorption issues by allowing direct oral mucosal absorption (though most of the dose is actually swallowed). The practical benefit over swallowed tablets is modest but not zero, and sublingual dosing is particularly useful in patients with severe atrophic gastritis or post-bariatric anatomy. Typical sublingual dose 1000-2000 mcg held under the tongue 5-10 minutes before swallowing.

PARENTERAL DOSING. Intramuscular (preferred) or deep subcutaneous hydroxocobalamin 1000 mcg is the standard parenteral dose. Loading schedule for newly diagnosed severe deficiency: 1000 mcg IM three times weekly for 2 weeks (or daily for 1 week, depending on protocol), then weekly for 4-8 weeks, then monthly for maintenance. Cyanocobalamin IM is an acceptable but inferior alternative (shorter half-life, requires more frequent dosing). Methylcobalamin IM is available in some jurisdictions (common in Japan for diabetic neuropathy) and is used at 500-1500 mcg weekly in that indication.

FORM CHOICE. As discussed in the mechanism section, differences between methylcobalamin, hydroxocobalamin, and cyanocobalamin at oral maintenance doses are modest. For most healthy users, cyanocobalamin is the cheapest and entirely adequate option. Methylcobalamin is preferred by users who want the "pre-converted" active form, who have cyanide sensitivity concerns (LHON, tobacco amblyopia), or who subjectively prefer it. Hydroxocobalamin is the preferred parenteral form globally. Adenosylcobalamin is less commonly used alone but appears in some combination products.

TIMING AND FOOD. B12 absorption is not meaningfully affected by food for synthetic supplemental forms (unlike food-bound B12 which requires acid release). Take B12 at a consistent time of day for habit formation. Morning or midday dosing is preferred over bedtime by users who report any stimulating effect (uncommon but reported). Cyanocobalamin is stable against food, acid, and bile; methylcobalamin is slightly less stable but adequate for oral dosing.

DURATION AND TAPERING. For pernicious anemia and irreversible absorption defects, B12 is lifelong. For repletion of reversible causes (dietary, metformin-associated), maintenance can often be at lower dose (500 mcg daily) once repletion is achieved. Chronic daily dosing is the norm; there is no need for cycling or breaks, and extended daily use produces no evidence of tolerance, accumulation toxicity, or diminishing returns.

UPPER LIMIT. The Institute of Medicine has not established an upper limit for B12 due to the absence of observed toxicity even at very high intakes. Doses of 10,000 mcg daily and higher have been administered in trials without adverse events. The practical ceiling is set by cost and the absence of additional benefit above 2000 mcg daily for most indications.

TESTING STRATEGY. Serum B12 below 200 pg/mL is generally considered deficient; 200-300 pg/mL is a "gray zone" where functional deficiency is common; above 300-400 pg/mL is usually adequate. MMA above 270-400 nmol/L suggests B12 deficiency even with normal serum B12. Homocysteine above 10-12 μmol/L suggests either B12, folate, or B6 insufficiency. Holotranscobalamin below 32 pmol/L is deficient; above 50 pmol/L is adequate. Test baseline, 3-6 months after starting supplementation to verify response, then annually if continuing indefinitely.

SPECIAL POPULATIONS. Pregnancy requires 2.6 mcg/day RDA and reasonable upper dosing; prenatal vitamins typically provide 8-12 mcg daily. Lactation requires 2.8 mcg/day RDA. Children: 0.4 mcg/day in infants, rising to 1.8 mcg in adolescents. Elderly (≥51): 2.4 mcg/day RDA, but most guidelines recommend the supplemental form rather than relying on food-bound B12. Vegans: 500-2000 mcg/day oral or sublingual. Post-bariatric surgery: 1000 mcg/day oral indefinitely (sleeve gastrectomy) or 1000 mcg/month IM (Roux-en-Y).